• Pneumonia Pathogen Analysis

    Currently Enrolling

    Pneumonia (infection in the lungs) is a common diagnosis in dogs and cats and can be caused by a variety of pathogens (i.e., bacteria, viruses, fungal organisms). Collecting fluid samples from the lungs of patients with pneumonia allows for tests to be performed that can identify the organism causing the infection.

    Study Details
  • Metabolomics Trial to Evaluate for Systemic Consequences of Intestinal Dysbiosis

    Currently Enrolling

    The intestinal microbiota are highly functional, with a combined genome (termed the microbiome) that is approximately 130-160 times larger than the human or canine genome. The microbiome is a highly functional organ and produces approximately 1,000 different metabolites, many of which have systemic effects in the dog. Intestinal dysbiosis is defined as an alteration in

    Study Details
  • Omics Research-Based Identification of Targets in Sepsis (ORBITS)

    Currently Enrolling

    Sepsis is caused by a severe infection that enters the bloodstream and is associated with a high mortality rate. This high mortality rate has remained unchanged over the last three decades even though there has been active research in the area.

    Study Details
  • Minimally Invasive Metastasectomy in Canines (MIMIC)

    Currently Enrolling

    Following removal of the primary tumor and adjuvant chemotherapy, the development of lung metastasis is the most common cause of mortality in dogs with osteosarcoma. A distinctive feature of lung metastases of osteosarcoma in human patients is the surprising benefit that can result from surgical resection of the lung nodules. The use of surgery to

    Study Details
  • Tolerability of Oral Paclitaxel in Cancer-Bearing Dogs

    Closed

    Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against  several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second drug, Encequidar, which improves this issue of poor

    Study Details
  • Cell-Based Therapy for Necrotizing Meningoencephalitis in Pugs

    Closed

    We propose that the spontaneous, but strongly genetic-based model of canine Necrotizing meningoencephalitis (NME) presents a unique way to help demonstrate the feasibility of inflammatory neurological disease prevention therapy.

    Study Details
  • Sepsis Risk in Dogs with Chemotherapy-Induced Neutropenia

    Closed

    Neutropenia (low white blood cell count) is a common side effect of chemotherapy in patients with cancer, with sepsis being a potential consequence. The timely identification and treatment of sepsis is paramount to the success of therapy.

    Study Details
  • Dysbiosis Enhancing Linkage Towards Association with Canine Hemangiosarcoma (DEL-HSA)

    Currently Enrolling

    Hemangiosarcoma (HSA) is an aggressive cancer in dogs and carries a poor prognosis. There are limited therapeutic options for the treatment of HSA, with none currently providing a significant opportunity for long-term survival.

    Study Details
  • Chronic Cannabidiol Administration and its Therapeutic Effect in Canine Epilepsy

    Closed

    This study is looking to evaluate the pharmacology profile of CBD in dogs (i.e. how it’s processed in the body) as well as its effectiveness in treating pain in dogs with chronic osteoarthritis. This study will hopefully result in similar studies being conducted in the fields of Neurology and Oncology.

    Study Details
  • Rapamycin for the Treatment of Hemangiosarcoma in Dogs

    Closed

    Based on its reported tolerability in dogs (alone and in combination with chemotherapy) this study will ask whether Rapamycin may improve treatment outcomes for dogs with hemangiosarcoma, and more precisely, to understand the hemangiosarcoma genotypes which may most benefit from its use.

    Study Details
  • Sorafenib for the Treatment of Solid Tumors in Dogs

    Closed

    We have previously reported on the tolerability and hints of clinical activity of Sorafenib in dogs with cancer. This background provides a rationale for the further study of Sorafenib in dogs with cancer. In this study we seek to define an optimal dosing schedule for Sorafenib and will assess its tolerability and activity in dogs with solid tumors.

    Study Details
  • Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (Ethos-PUSH)

    Currently Enrolling

    Ethos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of Hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.

    Study Details
Load More
Loading